Please assess the completion status of the following clinical trial:

Trial Title: Fecal Transplantation for Primary Clostridium Difficile Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients, ≥18 years with primary C. difficile infection, defined by the following three criteria:~  1. Diarrhea as defined by the WHO (≥3 loose stools per day), and~ 2. Positive stool test for toxin producing C. difficile, and~ 3. No evidence of previous C. difficile infection during 365 days before enrolment.~* Written informed consent~Exclusion Criteria:~* Known presence of other stool pathogens known to cause diarrhea.~* Ongoing antibiotic treatment for other infections that cannot be stopped before study treatment administration.~* Inflammatory bowel disease or microscopic colitis.~* \&lt; 3 months life expectancy.~* Serious immunodeficiency, defined as one of the following:~  * Ongoing or recent chemotherapy and current or expected neutropenia with neutrophil count of \&lt; 500/μL.~ * Active severe immunocompromising disease.~* Inability to comply with protocol requirements.~* Need of intensive care.~* Known irritable bowel syndrome, diarrheal type.~* Pregnancy or nursing.~* Known or suspected toxic megacolon or ileus.~* Total or subtotal colectomy, ileostomy or colonostomy.~* Contraindications for rectal catheter insertion~* Known hypersensitivity or other contraindications to vancomycin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fecal microbiota transplantation (Type: EXPERIMENTAL): Fecal microbiota from healthy, screened stool donors at the University Hospital of North Norway. Patients will receive one FMT enema immediately after enrolment.
- Antibiotic treatment (Type: ACTIVE_COMPARATOR): Patients randomized to the control group will receive a ten-day course of oral vancomycin four times a day. This is according to international guidelines for primary C. difficile treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).